Compare GSK plc (GSK) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Star Bulk Carriers Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B). The key difference: GSK plc is far larger — about 26× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.17%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Star Bulk Carriers Corp for 24 Days on average.
| GSK | SBLK | |
|---|---|---|
Market Cap | $91.88B | $3.54B |
Volume | 7,730,529 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $61.18 | $32.49 |
52-Week Low | $43.24 | $16.79 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $111.88B | $4.22B |
Dividend Yield | 3.9% | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Star Bulk Carriers (SBLK) trades at $29.70, up slightly by 0.03% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company shows strong profitability with a net income margin of 23.87% and has beaten earnings estimates for the last three quarters. Recent news highlights robust Q2 results, a $0.90 dividend for H2 2026, and significant insider buying, reflecting confidence in the shipping sector's momentum.
The outlook for SBLK is positive, supported by earnings beats, a shareholder-friendly dividend policy, and analyst consensus leaning buy. Risks include exposure to volatile shipping rates and macroeconomic pressures on global trade. Investors may find value in its attractive valuation multiples and strong cash flow generation, but should monitor freight rate trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
